Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis
NCT ID: NCT01148264
Last Updated: 2016-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
23 participants
INTERVENTIONAL
2010-07-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting
NCT07208305
A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis
NCT01625923
Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting
NCT02143531
Olanzapine for the Treatment of Refractory Chronic Nausea and Vomiting
NCT02977741
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
NCT00020657
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
olanzapine
olanzapine
1x10mg per day for three days
metoclopramide
metoclopramide
3x10mg per day for three days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
olanzapine
1x10mg per day for three days
metoclopramide
3x10mg per day for three days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed IC
Exclusion Criteria
* drug abuse
* pregnancy
* high dose chemotherapy
* treatment with other antiemetic drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karin Jordan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Karin Jordan
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karin Jordan, MD
Role: PRINCIPAL_INVESTIGATOR
Martin-Luther-University Halle-Wittenberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Martin-Luther-University Halle-Wittenberg, Department for Oncology and Hematology, Ernst-Grube-Strasse 40
Halle, Saxony-Anhalt, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-018665-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
KKSH 079
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.